Brought to you by:
Endologix announces first patients treated with the Detour system
Endologix has shared in a press release that the first patients underwent percutaneous transmural arterial bypass (PTAB) using the Detour system since Food and Drug Administration (FDA) approval of the system was granted. PTAB with the Detour system treats complex peripheral…
SVS responds to New York Times article on overuse of vascular interventions
In an official Society response, SVS President Joseph Mills, MD, tackles recent coverage in the mainstream media of inappropriateness in vascular care. There have been several recently published articles by respected news media outlets highlighting the deeply concerning issue of…
Long-awaited FDA update finds data do not support excess mortality risk for paclitaxel-coated devices
[vc_row][vc_column][vc_column_text] In a letter to healthcare providers dated July 11, 2023, the Food and Drug Administration (FDA) communicates that the risk of mortality associated with paclitaxel-coated devices to treat peripheral arterial disease (PAD) is no longer supported based on data…
Surmodics receives FDA approval for the SurVeil drug-coated balloon
Surmodics has announced the receipt of Food and Drug Administration (FDA) approval for the SurVeil drug-coated balloon (DCB). A company press release notes that the SurVeil DCB may now be marketed and sold in the U.S. to physicians for percutaneous…
Vascular Verification Program registers first four hospitals in US—including UCSF
UC San Francisco Medical Center (UCSF) is among the first four hospitals in the U.S. to be verified as part of the American College of Surgeons’ (ACS) Vascular Verification Program (Vascular-VP), a quality program recently launched in partnership with the Society for…
Two-year DETOUR2 study results presented at VAM 2023
Endologix has announced the 24-month results of the DETOUR2 study, presented at VAM 2023, the annual meeting of the Society for Vascular Surgery (SVS), by one of the study’s principal investigators, Sean Lyden, MD, chairman of vascular surgery at the…
BEST-CLI investigators implore a move beyond endo vs. open ‘battle’ in the name of scientific advance
The principal investigators behind the BEST-CLI trial struck a conciliatory tone during the inaugural Frank J. Veith Distinguished Lecture yesterday morning in which they laid bare the blood, sweat and tears shed on their journey to complete the landmark study.…
Sex-related disparities in lower-extremity revascularization outcomes brought into focus
Women are more likely to undergo reintervention after lower extremity revascularization for peripheral arterial disease (PAD) compared to male patients with similar limb salvage and survival outcomes despite having fewer comorbidities, findings of a retrospective analysis presented during the William…
BEST-CLI vs. BASIL-2: Different questions yield different answers
Medical editor Malachi Sheahan III, MD, takes a look at seemingly conflicting results from the landmark BEST-CLI and BASIL-2 trials, and asks what they really reveal. This past April, BASIL-2 chief investigator Andrew Bradbury, MD, presented trial results at the…
‘Nobody believed us’: Vascular giant discusses overcoming skeptics to make specialty-defining breakthroughs
Malachi Sheahan III, MD, Vascular Specialist’s medical editor, speaks to living legend and limb-salvage pioneer Frank J. Veith, MD, on the contents of his hard-hitting new book, The Medical Jungle: A Pioneering Surgeon’s Battle to Revolutionize Vascular Care and Challenge…